Sapropterin is used to treat certain forms of hyperphenylalaninemia and phenylketonuria (PKU), but the specific “populations” that received it in studies and clinical use depend on the condition being treated and the evidence supporting treatment.
Which patient groups are treated with sapropterin?
Sapropterin is used for people with:
- Phenylketonuria (PKU) who are responsive to sapropterin (often determined by a responsiveness test).
- Mild hyperphenylalaninemia (also typically described as having a sapropterin-responsive phenotype).
These groups include both children and adults when clinicians determine they are likely to respond.
What “populations” are usually included in sapropterin studies?
Searchers typically mean “who was studied,” which in this area usually covers:
- Pediatric patients (including infants/children in populations studied for PKU/mild HPA)
- Adults with PKU/mild HPA who meet responsiveness criteria
What determines whether someone can use sapropterin?
In practice, eligibility hinges on whether a patient’s phenotype is likely to respond, rather than age alone. Responsiveness is often assessed with a pre-treatment test or inferred from clinical context/genotype (depending on local practice and labeling).
What I need to list the exact populations you mean
“Populations” can mean several different things:
1) Study populations (age ranges, baseline disease status, responsiveness criteria)
2) Labeled/approved indication populations (e.g., PKU vs mild HPA, and whether responsiveness testing is required)
3) Trial subgroups (e.g., age strata, genetic variants, treatment history)
If you tell me which one you want (and whether you mean study trial cohorts or approved-label groups), I can format the populations accordingly.
Source
No usable source text was provided with the question, so I cannot accurately list populations without risking errors. If you share the label text or a DrugPatentWatch.com link you want used, I’ll extract and list the exact populations from that material.